Immunocore (IMCR) Projected to Post Quarterly Earnings on Wednesday

Immunocore (NASDAQ:IMCR) is expected to post its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect the company to announce earnings of ($0.30) per share and revenue of $137.29 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Wednesday, November 12, 2025 at 7:00 AM ET.

Immunocore (NASDAQ:IMCR) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.01. Immunocore had a negative net margin of 5.70% and a negative return on equity of 5.40%. The company had revenue of $130.65 million for the quarter, compared to analysts’ expectations of $122.96 million. During the same period in the prior year, the company posted ($0.23) EPS. Immunocore’s revenue was up 30.0% compared to the same quarter last year. On average, analysts expect Immunocore to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Immunocore Stock Up 2.8%

Immunocore stock opened at $33.09 on Monday. The firm has a 50 day simple moving average of $33.87 and a 200 day simple moving average of $33.10. The company has a current ratio of 5.89, a quick ratio of 5.86 and a debt-to-equity ratio of 1.01. Immunocore has a 1-year low of $23.15 and a 1-year high of $39.33. The firm has a market capitalization of $1.67 billion, a price-to-earnings ratio of -82.73 and a beta of 0.78.

Insider Activity

In other news, insider David M. Berman sold 22,532 shares of the business’s stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $35.67, for a total transaction of $803,716.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 10.40% of the company’s stock.

Hedge Funds Weigh In On Immunocore

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Osaic Holdings Inc. increased its holdings in shares of Immunocore by 117.4% in the 2nd quarter. Osaic Holdings Inc. now owns 3,148 shares of the company’s stock worth $97,000 after buying an additional 1,700 shares during the last quarter. State of Tennessee Department of Treasury purchased a new position in Immunocore in the second quarter worth $132,000. Engineers Gate Manager LP bought a new position in Immunocore in the second quarter valued at $463,000. Oxford Asset Management LLP purchased a new stake in Immunocore during the second quarter valued at about $661,000. Finally, Orion Porfolio Solutions LLC lifted its stake in Immunocore by 4.5% during the second quarter. Orion Porfolio Solutions LLC now owns 23,965 shares of the company’s stock worth $752,000 after purchasing an additional 1,031 shares during the last quarter. Hedge funds and other institutional investors own 84.50% of the company’s stock.

Analyst Ratings Changes

IMCR has been the subject of several recent research reports. Wall Street Zen cut Immunocore from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. Wells Fargo & Company initiated coverage on Immunocore in a report on Friday. They set an “overweight” rating and a $60.00 target price for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Immunocore in a research report on Wednesday, October 8th. Guggenheim assumed coverage on shares of Immunocore in a report on Thursday, September 18th. They issued a “neutral” rating on the stock. Finally, Zacks Research cut shares of Immunocore from a “strong-buy” rating to a “hold” rating in a research note on Thursday, September 4th. Seven research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Immunocore presently has a consensus rating of “Moderate Buy” and a consensus target price of $60.89.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.